Leveraging Novel Antibody-Drug Conjugates in a World of Evolving Treatment Paradigms: A Pan-Tumor Perspective


Estimated Turnout

upto 100
Based on previous editions


Nov 2021
+1 more edition


Next edition likely in Nov 2022
Claim event to edit details

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing .. Read more medical education for physicians. Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. This online, on-demand virtual symposium brings together oncology thought leaders from around the globe to discuss the evolving world of antibody-drug conjugates (ADCs) in cancer treatment. The targeting of tumor cell surface antigens remains a key therapeutic approach in oncology. ADCs combine the specificity of a tumor-targeting antibody with a cytotoxic payload. In this educational program, these experts discuss the expanding therapeutic options provided by ADCs, how to optimize the use of these agents in clinical practice, and best approaches for biomarker assessment and management of adverse events. This educational program is directed toward a global audience of medical oncologists, pathologists, and fellows interested in the treatment of cancer.

  • Share your Experience
  • Organizer
Logo Follow Company

Physicians Education ResourceRenowned

USA109 Total Events / 34 Upcoming Events

More Events From The Organizer